var data={"title":"Idarubicin: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Idarubicin: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6354?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=idarubicin-patient-drug-information\" class=\"drug drug_patient\">see &quot;Idarubicin: Patient drug information&quot;</a> and <a href=\"topic.htm?path=idarubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Idarubicin: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708916\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Extravasation:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Idarubicin should be given slowly into a freely flowing intravenous infusion; it must never be given intramuscularly or subcutaneously. Severe local tissue necrosis can occur if there is extravasation during administration.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Myocardial toxicity:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">As is the case with other anthracyclines, the use of idarubicin can cause myocardial toxicity leading to congestive heart failure. Cardiac toxicity is more common in patients who have received prior anthracyclines or who have preexisting cardiac disease.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Bone marrow suppression:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">As is usual with antileukemic agents, severe myelosuppression occurs when idarubicin is used at effective therapeutic doses.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Experienced physician:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">It is recommended that idarubicin be administered only under the supervision of a physician who is experienced in leukemia chemotherapy and in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Hepatic impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Dosage should be reduced in patients with impaired hepatic function.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:0em;\">Dosage should be reduced in patients with impaired renal function.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181682\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Idamycin PFS</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181683\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Idamycin PFS</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181728\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antineoplastic Agent, Anthracycline;</li>\n      <li>\n        Antineoplastic Agent, Topoisomerase II Inhibitor</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181686\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:0em;display:inline\">Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;margin-top:2em;\">\n      <b>Acute myeloid leukemia (AML):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Manufacturer labeling: Induction: </i>12 mg/m<sup>2</sup>/day for 3 days (in combination with cytarabine); a second induction cycle may be administered if necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Indication-specific dosing:</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">AML, relapsed/refractory: FLAG-IDA regimen: 10 mg/m<sup>2</sup>/day for 3 days (in combination with fludarabine, cytarabine, and filgrastim); a second course was given for consolidation upon hematologic recovery (Parker 1997)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Acute promyelocytic leukemia (APL):</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">LPA 2005 (high-risk patients):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Induction (all patients): 12 mg/m<sup>2</sup>/day on days 2, 4, 6, and 8 (day 8 dose was omitted in patients &gt;70 years of age) in combination with ATRA (tretinoin) (Sanz 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Consolidation (patients &le;60 years of age): 5 mg/m<sup>2</sup>/day for 4 days in consolidation cycle 1 and 12 mg/m<sup>2</sup>/day for 1 day in consolidation cycle 3 (in combination with ATRA [tretinoin] and cytarabine) (Sanz 2010)</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">APML4 protocol (Iland 2012): Induction (age-adjusted dosing):</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &lt;60 years of age: 12 mg/m<sup>2</sup>/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age 61 to 70 years: 9 mg/m<sup>2</sup>/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide)</p>\n    <p style=\"text-indent:-2em;margin-left:8em;\">Age &gt;70 years of age: 6 mg/m<sup>2</sup>/day on days 2, 4, 6, and 8 (in combination with ATRA [tretinoin] and arsenic trioxide)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181707\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=idarubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Idarubicin: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011).</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Acute myeloid leukemia (AML) (off-label use):</b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Newly diagnosed (CCG-2961) (Lange 2008):</i></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Induction: IdaDCTER: Idarubicin 5 mg/m<sup>2</sup>/dose daily for 4 days on days 0 to 3 in combination with cytarabine, etoposide, thioguanine, and dexamethasone</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Consolidation:</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">IdaDCTER: Idarubicin 5 mg/m<sup>2</sup>/dose daily for 4 days on days 0 to 3 in combination with cytarabine, etoposide, thioguanine, and dexamethasone</p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">\n      <b>or</b></p>\n    <p style=\"text-indent:-2em;margin-left:6em;\">Idarubicin 12 mg/m<sup>2</sup>/dose daily for 3 days on days 0 to 2 in combination with fludarabine and cytarabine</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <i>Relapsed/refractory: </i>12 mg/m<sup>2</sup> once daily for 3 days on days 0 to 2 in combination with fludarabine and cytarabine (Dinndorf 1997; Leahey 1997)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181687\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181688\" class=\"block dor drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer's labeling; however, it does recommend that dosage reductions be made. Patients with S<sub>cr</sub> &ge;2 mg/dL did not receive treatment in many clinical trials. The following adjustments have been recommended (Aronoff 2007):</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Adults:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &gt;50 mL/minute: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl 10 to 50 mL/minute: Administer 75% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">CrCl &lt;10 mL/minute: Administer 50% of dose.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hemodialysis: Supplemental dose not needed.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous ambulatory peritoneal dialysis (CAPD): Supplemental dose not needed.</p>\n    <p style=\"text-indent:0em;\">Infants, Children, and Adolescents:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &gt;50 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment is necessary.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">GFR &le;50 mL/minute/1.73 m<sup>2</sup>: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Intermittent hemodialysis: Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Peritoneal dialysis (PD): Administer 75% of dose</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Continuous renal replacement therapy (CRRT): Administer 75% of dose</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181689\" class=\"block doh drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilirubin 2.6 to 5 mg/dL: Administer 50% of dose (Perry 2012)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bilirubin &gt;5 mg/dL: Avoid use</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F27864233\" class=\"block dot drugH1Div\"><span class=\"drugH1\">Dosing: Adjustment for Toxicity</span>\n    <p style=\"text-indent:0em;display:inline\">Manufacturer labeling: If patients experience severe mucositis during the first induction cycle, delay administration of the second cycle until mucositis has resolved; consider reducing the dose by 25%.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181660\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as hydrochloride [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Idamycin PFS: 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Generic: 5 mg/5 mL (5 mL); 10 mg/10 mL (10 mL); 20 mg/20 mL (20 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181645\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">Yes</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181664\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">IV: For IV administration only. Do not administer IM or SubQ; administer as slow injection over 10 to 15 minutes into a free-flowing IV solution of NS or D5W. In some pediatric protocols (off-label use), idarubicin was infused over 15 minutes or over at least 30 minutes (Lange 2008; Leahy 1997); refer to individual protocols for infusion rate details.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Vesicant; ensure proper needle or catheter placement prior to and during infusion; avoid extravasation.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">\n      <b>Extravasation management:</b> If extravasation occurs, stop infusion immediately and disconnect (leave cannula/needle in place); gently aspirate extravasated solution (do <b>NOT</b> flush the line); remove needle/cannula; elevate extremity. Initiate antidote (dexrazoxane or dimethyl sulfate [DMSO]). Apply dry cold compresses for 20 minutes 4 times daily for 1 to 2 days (Perez Fidalgo 2012); withhold cooling beginning 15 minutes before dexrazoxane infusion; continue withholding cooling until 15 minutes after infusion is completed. Topical DMSO should not be administered in combination with dexrazoxane; may lessen dexrazoxane efficacy.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>Dexrazoxane:</i> Adults: 1,000 mg/m<sup>2</sup> (maximum dose: 2,000 mg) IV (administer in a large vein remote from site of extravasation) over 1 to 2 hours days 1 and 2, then 500 mg/m<sup>2</sup> (maximum dose: 1,000 mg) IV over 1 to 2 hours day 3; begin within 6 hours of extravasation. Day 2 and day 3 doses should be administered at approximately the same time (&plusmn;3 hours) as the dose on day 1 (Mouridsen 2007; Perez Fidalgo 2012). <b>Note:</b> Reduce dexrazoxane dose by 50% in patients with moderate to severe renal impairment (CrCl &lt;40 mL/minute).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">\n      <i>DMSO:</i> Children and Adults: Apply topically to a region covering twice the affected area every 8 hours for 7 days; begin within 10 minutes of extravasation; do not cover with a dressing (Perez Fidalgo 2012).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F49132620\" class=\"block hazard drugH1Div\"><span class=\"drugH1\">Hazardous Drugs Handling Considerations</span>\n    <p style=\"text-indent:0em;\">Hazardous agent (NIOSH 2016 [group 1]).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use appropriate precautions for receiving, handling, administration, and disposal. Gloves (single) should be worn during receiving, unpacking, and placing in storage.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">NIOSH recommends double gloving, a protective gown, ventilated engineering controls (a class II biological safety cabinet or a compounding aseptic containment isolator), and closed system transfer devices (CSTDs) for preparation. Double gloving, a gown, and (if dosage form allows) CSTDs are required during administration (NIOSH 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181663\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Acute myeloid leukemia:</b> Treatment of acute myeloid leukemia (AML) in adults (in combination with other approved chemotherapy agents).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25726674\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>Acute myeloid leukemia (pediatric), newly diagnosed; Acute myeloid leukemia (pediatric), relapsed/refractory</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181737\" class=\"block mst drugH1Div\"><span class=\"drugH1\">Medication Safety Issues</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Sound-alike/look-alike issues: </span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">IDArubicin may be confused with DOXOrubicin, DAUNOrubicin, epiRUBicin, idaruCIZUmab, idelalisib</p>\n        <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Idamycin PFS may be confused with Adriamycin</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">High alert medication:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:4em;\">This medication is in a class the Institute for Safe Medication Practices (ISMP) includes among its list of drug classes which have a heightened risk of causing significant patient harm when used in error.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181652\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:0em;display:inline\">The relative cardiotoxicity of idarubicin compared to doxorubicin is unclear. Some investigators report no increase in cardiac toxicity for adults at cumulative oral idarubicin doses up to 540 mg/m<sup>2</sup>; other reports suggest a maximum cumulative intravenous dose of 150 mg/m<sup>2</sup>.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Cardiac failure (dose-related), ECG abnormalities (transient; includes atrial premature contractions, S-T wave changes, supraventricular tachycardia, ventricular premature contractions; generally asymptomatic and self-limiting)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Alopecia (25% to 30%), skin rash (11%), urticaria</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Vomiting (30% to 60%), gastrointestinal hemorrhage (30%), diarrhea (9% to 22%), stomatitis (11%), nausea</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Urine discoloration (darker yellow)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (effects are generally less severe with oral dosing), bone marrow suppression (nadir: 10 to 15 days; recovery: 21 to 28 days; primarily leukopenia; effects are generally less severe with oral dosing), thrombocytopenia (effects are generally less severe with oral dosing)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Increased serum bilirubin (&le;44%), increased serum transaminases (&le;44%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Radiation recall phenomenon</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Peripheral neuropathy, seizure</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Cardiomyopathy, hyperuricemia, myocarditis, typhlitis (neutropenic)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181667\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">There are no contraindications listed in the manufacturer's labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Documentation of allergenic cross-reactivity for drugs in this class is limited. However, because of similarities in chemical structure and/or pharmacologic actions, the possibility of cross-sensitivity cannot be ruled out with certainty.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181649\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Bone marrow suppression: <b>[US Boxed Warning]: Severe myelosuppression occurs when idarubicin is used at effective therapeutic doses.</b> Patients are at risk of developing infection and bleeding due to neutropenia and thrombocytopenia, respectively (may be fatal). Monitor blood counts frequently. Do not use in patients with preexisting bone marrow suppression unless the benefit outweighs the risk.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Extravasation: <b>[US Boxed Warning] Vesicant; may cause severe local tissue necrosis if extravasation occurs. For IV administration only; not for IM or SubQ administration. Administer through a freely flowing IV infusion line.</b> Ensure proper needle or catheter placement prior to and during infusion. Avoid extravasation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Gastrointestinal toxicity: Idarubicin is associated with a moderate emetic potential; antiemetics are recommended to prevent nausea and vomiting (Dupuis 2011; Hesketh 2017; Roila 2016). Abdominal pain, diarrhea, and mucositis may commonly occur. Severe enterocolitis with perforation has been reported (rare).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hyperuricemia: Rapid lysis of leukemic cells may lead to hyperuricemia. Ensure adequate hydration and consider use of antihyperuricemic prophylaxis.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Myocardial toxicity: <b>[US Boxed Warning]: Idarubicin may cause myocardial toxicity leading to heart failure. Cardiotoxicity is more common in patients who have previously received anthracyclines or have preexisting cardiac disease.</b> The risk of myocardial toxicity is also increased in patients with concomitant or prior mediastinal/pericardial irradiation, patients with anemia, bone marrow depression, infections, leukemic pericarditis, or myocarditis. Patients with active or dormant cardiovascular disease, concurrent administration of cardiotoxic drugs, prior therapy with other anthracyclines or anthracenediones are also at increased risk for cardiotoxicity. Other risk factors for anthracycline-induced cardiotoxicity include &ge;60 years of age at time of treatment and &ge;2 cardiovascular risk factors (smoking, hypertension, diabetes, dyslipidemia, or obesity) during or after treatment (Armenian 2017). Potentially fatal heart failure, acute arrhythmias (may be life-threatening) or other cardiomyopathies may also occur. Regular monitoring of LVEF is recommended, especially in patients with cardiac risk factors or impaired cardiac function. The half-life of other cardiotoxic agents must be considered. Avoid the use of anthracycline-based therapy for at least 5 half-lives after discontinuation of the cardiotoxic agent. Monitor cardiac function during treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease-related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hepatic impairment: <b>[US Boxed Warning]: Dosage reductions are recommended in patients with hepatic impairment.</b> Idarubicin use is not recommended if bilirubin &gt;5 mg/dL.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Infections: Systemic infections should be controlled prior to initiation of treatment.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Dosage reductions are recommended in patients with renal impairment.</b></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions may exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Special populations:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Elderly: Patients &gt;60 years of age who were undergoing induction therapy experienced heart failure, serious arrhythmias, chest pain, MI, and asymptomatic declines in LVEF more frequently than younger patients.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Experienced physician: <b>[US Boxed Warning]: Should be administered under the supervision of an experienced cancer chemotherapy physician.</b> <b>Use in facilities with laboratory and supportive resources adequate to monitor drug tolerance and protect and maintain a patient compromised by drug toxicity. The physician and institution must be capable of responding rapidly and completely to severe hemorrhagic conditions and/or overwhelming infection.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F9838176\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Substrate</b> of P-glycoprotein/ABCB1</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181654\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8549&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Ado-Trastuzumab Emtansine: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with ado-trastuzumab emtansine should avoid anthracycline-based therapy for up to 7 months after stopping ado-trastuzumab emtansine.  Monitor closely for cardiac dysfunction in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Immunosuppressants may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">BCG (Intravesical): Myelosuppressive Agents may diminish the therapeutic effect of BCG (Intravesical). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Bevacizumab: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cardiac Glycosides: May diminish the cardiotoxic effect of Anthracyclines. Anthracyclines may decrease the serum concentration of Cardiac Glycosides. The effects of liposomal formulations may be unique from those of the free drug, as liposomal formulation have unique drug disposition and toxicity profiles, and liposomes themselves may alter digoxin absorption/distribution.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Chloramphenicol (Ophthalmic): May enhance the adverse/toxic effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CloZAPine: Myelosuppressive Agents may enhance the adverse/toxic effect of CloZAPine. Specifically, the risk for neutropenia may be increased. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Coccidioides immitis Skin Test: Immunosuppressants may diminish the diagnostic effect of Coccidioides immitis Skin Test. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Cyclophosphamide: May enhance the cardiotoxic effect of Anthracyclines.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Deferiprone: Myelosuppressive Agents may enhance the neutropenic effect of Deferiprone. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Denosumab: May enhance the adverse/toxic effect of Immunosuppressants. Specifically, the risk for serious infections may be increased.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Dipyrone: May enhance the adverse/toxic effect of Myelosuppressive Agents. Specifically, the risk for agranulocytosis and pancytopenia may be increased<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Echinacea: May diminish the therapeutic effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Fingolimod: Immunosuppressants may enhance the immunosuppressive effect of Fingolimod.  Management: Avoid the concomitant use of fingolimod and other immunosuppressants when possible. If combined, monitor patients closely for additive immunosuppressant effects (eg, infections).<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Leflunomide: Immunosuppressants may enhance the adverse/toxic effect of Leflunomide. Specifically, the risk for hematologic toxicity such as pancytopenia, agranulocytosis, and/or thrombocytopenia may be increased.  Management: Consider not using a leflunomide loading dose in patients receiving other immunosuppressants.  Patients receiving both leflunomide and another immunosuppressant should be monitored for bone marrow suppression at least monthly.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lenograstim: Antineoplastic Agents may diminish the therapeutic effect of Lenograstim.  Management: Avoid the use of lenograstim 24 hours before until 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lipegfilgrastim: Antineoplastic Agents may diminish the therapeutic effect of Lipegfilgrastim.  Management: Avoid concomitant use of lipegfilgrastim and myelosuppressive cytotoxic chemotherapy. Lipegfilgrastim should be administered at least 24 hours after the completion of myelosuppressive cytotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Lumacaftor: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. Lumacaftor may increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Natalizumab: Immunosuppressants may enhance the adverse/toxic effect of Natalizumab. Specifically, the risk of concurrent infection may be increased. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Nivolumab: Immunosuppressants may diminish the therapeutic effect of Nivolumab. <i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ocrelizumab: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Palifermin: May enhance the adverse/toxic effect of Antineoplastic Agents. Specifically, the duration and severity of oral  mucositis may be increased. Management: Do not administer palifermin within 24 hours before, during infusion of, or within 24 hours after administration of myelotoxic chemotherapy.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inducers: May decrease the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inducers may also further limit the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">P-glycoprotein/ABCB1 Inhibitors: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates. P-glycoprotein inhibitors may also enhance the distribution of p-glycoprotein substrates to specific cells/tissues/organs where p-glycoprotein is present in large amounts (e.g., brain, T-lymphocytes, testes, etc.).<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pidotimod: Immunosuppressants may diminish the therapeutic effect of Pidotimod. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pimecrolimus: May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Promazine: May enhance the myelosuppressive effect of Myelosuppressive Agents.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Ranolazine: May increase the serum concentration of P-glycoprotein/ABCB1 Substrates.<i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Roflumilast: May enhance the immunosuppressive effect of Immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Sipuleucel-T: Immunosuppressants may diminish the therapeutic effect of Sipuleucel-T. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Topical): May enhance the adverse/toxic effect of Immunosuppressants.<i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Taxane Derivatives: May enhance the adverse/toxic effect of Anthracyclines. Taxane Derivatives may increase the serum concentration of Anthracyclines. Taxane Derivatives may also increase the formation of toxic anthracycline metabolites in heart tissue.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tertomotide: Immunosuppressants may diminish the therapeutic effect of Tertomotide. <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tofacitinib: Immunosuppressants may enhance the immunosuppressive effect of Tofacitinib.  Management: Concurrent use with antirheumatic doses of methotrexate or nonbiologic disease modifying antirheumatic drugs (DMARDs) is permitted, and this warning seems particularly focused on more potent immunosuppressants.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Trastuzumab: May enhance the cardiotoxic effect of Anthracyclines. Management: When possible, patients treated with trastuzumab should avoid anthracycline-based therapy for up to 7 months after stopping trastuzumab.  Monitor closely for cardiac dysfunction in patients receiving anthracyclines with trastuzumab.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Inactivated): Immunosuppressants may diminish the therapeutic effect of Vaccines (Inactivated).  Management: Vaccine efficacy may be reduced. Complete all age-appropriate vaccinations at least 2 weeks prior to starting an immunosuppressant. If vaccinated during immunosuppressant therapy, revaccinate at least 3 months after immunosuppressant discontinuation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Vaccines (Live): Immunosuppressants may enhance the adverse/toxic effect of Vaccines (Live). Immunosuppressants may diminish the therapeutic effect of Vaccines (Live).  Management: Avoid use of live organism vaccines with immunosuppressants; live-attenuated vaccines should not be given for at least 3 months after immunosuppressants.<i> Risk X: Avoid combination</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14206274\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;\">Adverse events were observed in animal reproduction studies. Fetal fatality was noted in a case report following second trimester exposure in a pregnant woman.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Guidelines for diagnosis, treatment, and follow-up of cancer during pregnancy from the European Society for Medical Oncology (ESMO) suggest utilizing an anthracycline agent other than idarubicin (in combination with cytarabine) for induction treatment in acute myeloid leukemia (AML) and only in the second and third trimester; the guidelines also recommend referral to a facility with expertise in cancer during pregnancy and a multidisciplinary team (obstetrician, neonatologist, oncology team) is encouraged (Peccatori 2013).</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">The manufacturer recommends that women of reproductive potential avoid pregnancy during treatment.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F20620004\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">It is not known if idarubicin is present in breast milk. Due to the potential for serious adverse reactions in the breastfed infant, breastfeeding is not recommended by the manufacturer.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181658\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">CBC with differential and platelet count (frequently), cardiac function (LVEF; prior and during treatment), serum electrolytes, renal function (serum creatinine; prior to and during treatment), uric acid, liver function (ALT, AST, bilirubin; prior to and during treatment); monitor infusion site for signs of extravasation; monitor for gastrointestinal toxicity and infection</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181648\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Idarubicin inhibits DNA and RNA synthesis by intercalation between DNA base pairs and by steric obstruction. Although the exact mechanism is unclear, it appears that direct binding to DNA (intercalation) and inhibition of DNA repair (topoisomerase II inhibition) result in blockade of DNA and RNA synthesis and fragmentation of DNA.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181666\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Distribution: V<sub>dss</sub>: 1,500 L/m<sup>2</sup> (Robert 1993); extensive tissue binding; CSF</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Protein binding: 94% (idarubicinol) to 97% (idarubicin)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Metabolism: Hepatic to idarubicinol (active metabolite)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Half-life elimination:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Children: Children &ge;1 year of age and adolescents: 17.6 &plusmn; 6.8 hours (range: 8.3 to 29.6 hours) (Reid 1990)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Adults: Adults: 22 hours (range: 4 to 48 hours); &gt;45 hours (idarubicinol)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Excretion: Primarily biliary; urine (8 to 10% as idarubicinol, ~2% to 5% as unchanged drug [Robert 1993])</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323191\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Idamycin PFS Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $63.72</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $127.42</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/20 mL (20 mL): $244.66</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (IDArubicin HCl Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">5 mg/5 mL (5 mL): $92.70</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">10 mg/10 mL (10 mL): $160.66</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">20 mg/20 mL (20 mL): $275.63</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F181670\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Idamycin (MX);</li>\n      <li>Idaralem (CR, DO, GT, HN, MX, NI, PA, SV, TH);</li>\n      <li>Ondarubin (CR, DO, GT, HN, MX, NI, PA, SV);</li>\n      <li>Zavedos (AE, AR, AT, AU, BE, BG, BH, BR, CH, CL, CN, CO, CY, CZ, DE, DK, EC, EE, EG, ES, FI, FR, GB, GR, HK, HN, HR, HU, IE, IL, IN, IQ, IR, IS, IT, JO, KR, KW, LB, LT, LU, LV, LY, MT, MY, NL, NO, NZ, OM, PE, PH, PK, PL, PT, QA, RO, RU, SA, SE, SI, SK, SY, TH, TR, TW, UY, VE, YE, ZA);</li>\n      <li>Zavedos CS (SG);</li>\n      <li>Zavel (KR);</li>\n      <li>Zaverucin (VN)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Armenian SH, Lacchetti C, Barac A, et al. Prevention and monitoring of cardiac dysfunction in survivors of adult cancers: American Society of Clinical Oncology clinical practice guideline. <i>J Clin Oncol</i>. 2017;35(8):893-911. doi: 10.1200/JCO.2016.70.5400.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/27918725/pubmed\" target=\"_blank\" id=\"27918725\">27918725</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aronoff GR, Bennett WM, Berns JS, et al. <i>Drug Prescribing in Renal Failure: Dosing Guidelines for Adults and Children</i>, 5th ed. Philadelphia, PA: American College of Physicians; 2007, p 100, 172.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9256119\"></a>Dinndorf PA, Avramis VI, Wiersma S, et al. Phase I/II study of idarubicin given with continuous infusion fludarabine followed by continuous infusion cytarabine in children with acute leukemia: a report from the Children's Cancer Group. <i>J Clin Oncol</i>. 1997;15(8):2780-2785.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/9256119/pubmed\" target=\"_blank\" id=\"9256119\">9256119</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Dupuis LL, Boodhan S, Sung L, et al; Pediatric Oncology Group of Ontario. Guideline for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patients. <i>Pediatr Blood Cancer</i>. 2011;57(2):191-198.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/21465637/pubmed\" target=\"_blank\" id=\"21465637\">21465637</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Floyd JD, Nguyen DT, Lobins RL, et al. Cardiotoxicity of cancer therapy. <i>J Clin Oncol</i>. 2005;23(30):7685-7696.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/16234530/pubmed\" target=\"_blank\" id=\"16234530\">16234530</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology clinical practice guideline update. <i>J Clin Oncol</i>. 2017;35(28):3240-3261. doi: 10.1200/JCO.2017.74.4789.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/28759346/pubmed\" target=\"_blank\" id=\"28759346\">28759346</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idamycin PFS (idarubicin hydrochloride) [prescribing information]. New York, NY: Pfizer; August 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Idarubicin (prescribing information). Schaumburg, IL: APP Pharmaceuticals, LLC; December 2008.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Iland HJ, Bradstock K, Supple SG, et al. All-trans-retinoic acid, idarubicin, and IV arsenic trioxide as initial therapy in acute promyelocytic leukemia (APML4). <i>Blood</i>. 2012;120(8):1570-1580.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/22715121/pubmed\" target=\"_blank\" id=\"22715121\">22715121</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"18000167\"></a>Lange BJ, Smith FO, Feusner J, et al. Outcomes in CCG-2961, a children's oncology group phase 3 trial for untreated pediatric acute myeloid leukemia: a report from the children's oncology group. <i>Blood</i>. 2008;111(3):1044-1053.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/18000167/pubmed\" target=\"_blank\" id=\"18000167\">18000167</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"9256828\"></a>Leahey A, Kelly K, Rorke LB, et al. A phase I/II study of idarubicin (Ida) with continuous infusion fludarabine (F-ara-A) and cytarabine (ara-C) for refractory or recurrent pediatric acute myeloid leukemia (AML). <i>J Pediatr Hematol Oncol</i>. 1997; 19(4):304-308.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/9256828/pubmed\" target=\"_blank\" id=\"9256828\">9256828</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morgan C, Tillett T, Braybrooke J, et al. Management of uncommon chemotherapy-induced emergencie. <i>Lancet Oncol</i>. 2011;12(8):806-814.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/21276754/pubmed\" target=\"_blank\" id=\"21276754\">21276754</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Mouridsen HT, Langer SW, Buter J, et al. Treatment of anthracycline extravasation with Savene (Dexrazoxane): results from two prospective clinical multicentre studies. <i>Ann Oncol</i>. 2007;18(3):546-550.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/17185744/pubmed\" target=\"_blank\" id=\"17185744\">17185744</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Parker JE, Pagliuca A, Mijovic A, et al. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of poor-risk myelodysplastic syndromes and acute myeloid leukaemia. <i>Br J Haematol</i>. 1997;99(4):939-944.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/9432047/pubmed\" target=\"_blank\" id=\"9432047\">9432047</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Peccatori FA, Azim HA Jr, Orecchia R, et al; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Ann Oncol</i>. 2013;24(suppl 6):vi160-170. doi: 10.1093/annonc/mdt199.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/23813932/pubmed\" target=\"_blank\" id=\"23813932\">23813932</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    P&eacute;rez Fidalgo JA, Garc&iacute;a Fabregat L, Cervantes A, et al. Management of chemotherapy extravasation: ESMO-EONS Clinical Practice Guidelines. <i>Ann Oncol</i>. 2012;23(Suppl 7):167-173.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/22997449/pubmed\" target=\"_blank\" id=\"22997449\">22997449</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Perry MC. <i>Chemotherapeutic Agents: Idarubicin in The Chemotherapy Source Book</i>. 5th ed. Philadelphia, PA: 2012.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Reid JM, Pendergrass TW, Krailo MD, et al, &ldquo;Plasma Pharmacokinetics and Cerebrospinal Fluid Concentrations of Idarubicin and Idarubicinol in Pediatric Leukemia Patients: A Children's Cancer Study Group Report,&rdquo; <i>Cancer Res</i>, 1990, 50(20):6525-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/2208112/pubmed\" target=\"_blank\" id=\"2208112\">2208112</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Robert J. Clinical pharmacokinetics of idarubicin. <i>Clin Pharmacokinet</i>. 1993;24(4):275-288.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/8491056/pubmed\" target=\"_blank\" id=\"8491056\">8491056</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Roila F, Molassiotis A, Herrstedt J, et al. 2016 MASCC and ESMO guideline update for the prevention of chemotherapy- and radiotherapy-induced nausea and vomiting and of nausea and vomiting in advanced cancer patients. <i>Ann Oncol</i>. 2016;27(suppl 5):v119-v133. doi: 10.1093/annonc/mdw270<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/27664248/pubmed\" target=\"_blank\" id=\"27664248\">27664248</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Sanz MA, Montesinos P, Rayon C, et al. Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. <i>Blood</i>. 2010;115(25):137-146.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/idarubicin-drug-information/abstract-text/20393132/pubmed\" target=\"_blank\" id=\"20393132\">20393132</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services; Centers for Disease Control and Prevention; National Institute for Occupational Safety and Health. NIOSH list of antineoplastic and other hazardous drugs in healthcare settings 2016. <a href=\"http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf\" target=\"_blank\">http://www.cdc.gov/niosh/topics/antineoplastic/pdf/hazardous-drugs-list_2016-161.pdf</a>. Updated September 2016. Accessed October 5, 2016.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8549 Version 159.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708916\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F181682\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F181683\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F181728\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F181686\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F181707\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F181687\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment\" href=\"#F181688\" class=\"outlineLink\">Dosing: Renal Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment\" href=\"#F181689\" class=\"outlineLink\">Dosing: Hepatic Impairment</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adjustment for Toxicity\" href=\"#F27864233\" class=\"outlineLink\">Dosing: Adjustment for Toxicity</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F181660\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F181645\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F181664\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Hazardous Drugs Handling Considerations\" href=\"#F49132620\" class=\"outlineLink\">Hazardous Drugs Handling Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F181663\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25726674\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Medication Safety Issues\" href=\"#F181737\" class=\"outlineLink\">Medication Safety Issues</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F181652\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F181667\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F181649\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F9838176\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F181654\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F14206274\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F20620004\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F181658\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F181648\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F181666\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323191\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F181670\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8549|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=idarubicin-patient-drug-information\" class=\"drug drug_patient\">Idarubicin: Patient drug information</a></li><li><a href=\"topic.htm?path=idarubicin-pediatric-drug-information\" class=\"drug drug_pediatric\">Idarubicin: Pediatric drug information</a></li></ul></div></div>","javascript":null}